Effect of a GnRH injection on kisspeptin levels in girls with suspected precocious puberty: a randomized-controlled pilot study

What Was Tested

The paper reports a study of Kisspeptin-10, published as a randomized controlled trial.

Kisspeptin plays a major role in the onset of puberty by stimulating the gonadotropin-releasing hormone (GnRH) neurons.

The aim of this study was to investigate whether GnRH inhibits kisspeptin secretion via a negative feedback mechanism and potential associations between kisspeptin levels and other hormones of importance for pubertal onset.

Who Took Part

The age groups tagged for this paper are children, women only.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and pilot study.

Because people in this Kisspeptin-10 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Kisspeptin-10, giving a reference point.

It is described as a pilot, a small early test of whether a larger Kisspeptin-10 study would be practical.

Thirteen girls with suspected central precocious puberty underwent a GnRH stimulation test twice in a randomized, placebo-controlled manner.

Blood was sampled up to 150 min after an IV injection of either Relefact LHRH® or saline.

The levels of kisspeptin, acylated ghrelin, ultrasensitive oestradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH), insulin and glucose were analysed.

What Was Measured

PubMed files the paper under topics including Puberty, Precocious, Kisspeptins, Gonadotropin-Releasing Hormone, Pilot Projects, Luteinizing Hormone, Follicle Stimulating Hormone and Biomarkers.

The authors tagged it with the keywords hypothalamic-pituitary-gonadal axis and precocious puberty.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and pilot study of Kisspeptin-10.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Kisspeptin-10 compound page, all human trials.